Parents
Sign in to add mentor| Anne Cambon-Thomsen | grad student | 2002 | Toulouse 3 | |
| (Identification de marqueurs génétiques associés à la sévérité de la polyarthrite rhumatoïde selon une approche gènes candidats) | ||||
| Alain Cantagrel | grad student | 2002 | Toulouse 3 | |
| (Identification de marqueurs génétiques associés à la sévérité de la polyarthrite rhumatoïde selon une approche gènes candidats) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fautrel B, Kedra J, Rempenault C, et al. (2024) 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis. Joint Bone Spine. 91: 105790 |
| Ruyssen-Witrand A, Guernec G, Dupont J, et al. (2023) Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity. Arthritis Research & Therapy. 25: 207 |
| Laroche M, Degboe Y, Constantin A. (2022) Sjögren's syndrome associated with erosive rheumatoid arthritis alters its prognosis and long-term therapeutic response: a case-control study. Rheumatology International |
| Diallo K, Simons N, Sayegh S, et al. (2021) Evidence for tmTNF reverse signaling : Implications for an arginase-1-mediated therapeutic effect of TNF inhibitors during inflammation. Iscience. 24: 102331 |
| Hilliquin P, Barnetche T, Baillet A, et al. (2020) Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study. Rheumatology and Therapy |
| Degboé Y, Schiff M, Weinblatt M, et al. (2020) Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. Journal of Clinical Medicine. 9 |
| Vinson D, Molet-Benhamou L, Degboé Y, et al. (2020) Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Research & Therapy. 22: 97 |
| Simons N, Degboé Y, Barnetche T, et al. (2020) Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. Clinical and Experimental Rheumatology |
| Rauwel B, Degboé Y, Nigon D, et al. (2020) Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients. Arthritis Research & Therapy. 22: 13 |
| Ruyssen-Witrand A, Rousseau V, Sommet A, et al. (2020) Op0314 Factors Associated With 5-Year Drug-Free Remission In Early Onset Axial Spondyloarthritis Patients: Data From Desir Cohort Annals of the Rheumatic Diseases. 79: 194-194 |